• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
Cell Transplant. 2022 Jan-Dec;31:9636897221113789. doi: 10.1177/09636897221113789.ABSTRACTIn this multicenter phase II study, we evaluated the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) and evaluated the quality of life (QOL) of the enrolled patients using the Short Form 36 (SF-36) health survey questionnaire. Thirty-six patients who were diagnosed with steroid-refractory cGVHD and treated with imatinib between March 2013 and February 2019 received 100 mg/day of imatinib for 2 weeks. Depending on the patient's condition and investigator's decision, the imati...
Source: Cell Transplantation - July 21, 2022 Category: Cytology Authors: Dong Won Baek Hee Jeong Cho Ju-Hyung Kim Jae Sook Ahn Hyeoung-Joon Kim Sung Nam Lim Jun Won Cheong Sung-Yong Kim Ho Sup Lee Jong Ho Won Ho-Young Yhim Sang Kyun Sohn Joon Ho Moon Source Type: research

He ’s the First African American to Receive a Face Transplant. His Story Could Change Health Care
Robert Chelsea turned down the first face he was offered. It was a fine face, one that could have taken him off the transplant waiting list after just a couple months. But Chelsea—severely disfigured after a catastrophic car accident five years earlier—was in no hurry. He’d gotten used to tilting his head back so food and water wouldn’t fall out of his nearly lipless mouth. He knew how to respond compassionately to children who stared in shock and fear. The face, offered in May 2018, had belonged to a man with skin that was much fairer than what remained of Chelsea’s—so light that Chelse...
Source: TIME: Health - October 24, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Healthcare Source Type: news